Last reviewed · How we verify
AllerT full dose
At a glance
| Generic name | AllerT full dose |
|---|---|
| Also known as | AllerT 50-100 micrograms |
| Sponsor | Anergis |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AllerT full dose CI brief — competitive landscape report
- AllerT full dose updates RSS · CI watch RSS
- Anergis portfolio CI